BRTX
BioRestorative Therapies, Inc.NASDAQHealthcare$0.28-9.71%ClosedMarket Cap: $2.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.25
P/S
6.28
EV/EBITDA
-0.05
DCF Value
$-4.84
FCF Yield
-481.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.1%
Operating Margin
-4350.1%
Net Margin
-3959.4%
ROE
-420.3%
ROA
-349.1%
ROIC
-4386.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $19.6K | -177.9% | $-3.8M | $-3.2M | $-0.36 | — |
| FY 2025 | $359.7K | 93.4% | $-15.6M | $-14.2M | $-1.58 | — |
| Q3 2025 | $11.8K | -435.5% | $-3.7M | $-3.0M | $-0.33 | — |
| Q2 2025 | $303.3K | 97.1% | $-3.3M | $-2.7M | $-0.30 | — |
| Q1 2025 | $25.0K | 88.4% | $-4.8M | $-5.3M | $-0.64 | — |
| Q4 2024 | $43.3K | 92.3% | $-2.7M | $-1.6M | $-0.21 | — |
| FY 2024 | $401.0K | 93.0% | $-11.6M | $-9.0M | $-1.16 | — |
| Q3 2024 | $233.6K | 92.2% | $-2.3M | $-1.1M | $-0.13 | — |
| Q2 2024 | $89.1K | 92.7% | $-2.5M | $-4.0M | $-0.50 | — |
| Q1 2024 | $35.0K | 100.0% | $-4.1M | $-2.2M | $-0.33 | — |
| Q4 2023 | $19.3K | -121.3% | $-3.2M | $1.2M | $0.25 | — |
| FY 2023 | $145.8K | 100.0% | $-15.2M | $-10.4M | $-2.47 | — |